145 related articles for article (PubMed ID: 38242556)
21. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Sankar MJ; Sankar J; Chandra P
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
[TBL] [Abstract][Full Text] [Related]
22. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
23. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma.
Chehrazi-Raffle A; Meza L; Alcantara M; Dizman N; Bergerot P; Salgia N; Hsu J; Ruel N; Salgia S; Malhotra J; Karczewska E; Kortylewski M; Pal S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688021
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents.
Tozer K; Roller AB; Chong LP; Sadda S; Folk JC; Mahajan VB; Russell SR; Boldt HC; Sohn EH
Ophthalmology; 2013 Oct; 120(10):2029-34. PubMed ID: 23714319
[TBL] [Abstract][Full Text] [Related]
25. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
[TBL] [Abstract][Full Text] [Related]
26. Thyroid disorders associated with immune control point inhibitors.
Fidilio E; Navarro-González E; Romero-Lluch AR; Iglesias P; Diez Gómez JJ; Anda Apiñániz E; Santos Mazo E; Zafón C
Endocrinol Diabetes Nutr (Engl Ed); 2021; 68(6):408-415. PubMed ID: 34742474
[TBL] [Abstract][Full Text] [Related]
27. Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?
Perazella MA; Shirali AC
Kidney Int; 2020 Jan; 97(1):62-74. PubMed ID: 31685311
[TBL] [Abstract][Full Text] [Related]
28. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center.
Izzedine H; Escudier B; Lhomme C; Pautier P; Rouvier P; Gueutin V; Baumelou A; Derosa L; Bahleda R; Hollebecque A; Sahali D; Soria JC
Medicine (Baltimore); 2014 Nov; 93(24):333-339. PubMed ID: 25500702
[TBL] [Abstract][Full Text] [Related]
29. Proteinuria and VEGF-targeted therapies:
an underestimated toxicity?
Izzedine H; Soria JC; Escudier B
J Nephrol; 2013; 26(5):807-10. PubMed ID: 24052461
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
Cortazar FB; Marrone KA; Troxell ML; Ralto KM; Hoenig MP; Brahmer JR; Le DT; Lipson EJ; Glezerman IG; Wolchok J; Cornell LD; Feldman P; Stokes MB; Zapata SA; Hodi FS; Ott PA; Yamashita M; Leaf DE
Kidney Int; 2016 Sep; 90(3):638-47. PubMed ID: 27282937
[TBL] [Abstract][Full Text] [Related]
31. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
Hanna RM; Barsoum M; Arman F; Selamet U; Hasnain H; Kurtz I
Kidney Int; 2019 Sep; 96(3):572-580. PubMed ID: 31229276
[TBL] [Abstract][Full Text] [Related]
32. Vascular Endothelial Growth Factor Inhibitor Therapy and Cardiovascular and Renal Damage in Renal Cell Carcinoma.
Lai S; Molfino A; Seminara P; Longo F; Innico G; Coppola B; Mastroluca D; Galani A; Dimko M; Aceto P; Lai C
Curr Vasc Pharmacol; 2018 Jan; 16(2):190-196. PubMed ID: 28676023
[TBL] [Abstract][Full Text] [Related]
33. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.
Tesařová P; Tesař V
Folia Biol (Praha); 2013; 59(1):15-25. PubMed ID: 23537524
[TBL] [Abstract][Full Text] [Related]
34. The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of early phase trials.
Saeed A; Park R; Sun W
J Hematol Oncol; 2021 Jan; 14(1):13. PubMed ID: 33436042
[TBL] [Abstract][Full Text] [Related]
35. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).
Cosmai L; Gallieni M; Liguigli W; Porta C
J Nephrol; 2017 Apr; 30(2):171-180. PubMed ID: 27154025
[TBL] [Abstract][Full Text] [Related]
36. Current Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features.
Tonooka A; Ohashi R
J Nippon Med Sch; 2022 May; 89(2):128-138. PubMed ID: 34840210
[TBL] [Abstract][Full Text] [Related]
37. Crescentic Fibrillary Glomerulonephritis in the Setting of Immune Checkpoint Inhibitor Therapy: A Report of Two Cases.
DiFranza LT; Chafouleas E; Katipally S; Stokes MB; Kudose S; Sekulic M
Glomerular Dis; 2023; 3(1):69-74. PubMed ID: 37113492
[TBL] [Abstract][Full Text] [Related]
38. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
[TBL] [Abstract][Full Text] [Related]
39. Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report.
Kyriazis P; Tiwary A; Freeman J; Landry D; Braden G
J Med Case Rep; 2021 Apr; 15(1):186. PubMed ID: 33810799
[TBL] [Abstract][Full Text] [Related]
40. Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study).
Nakamura M; Funakoshi T; Kataoka S; Horimatsu T; Nishikawa Y; Matsubara T; Mizukami T; Goto T; Tsuchihashi K; Baba E; Tsumura T; Mihara Y; Hamaguchi T; Yanagita M; Muto M
BMC Cancer; 2022 May; 22(1):515. PubMed ID: 35525917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
